NCT01910051
Completed
Not Applicable
Explorative Assessment of Biomarkers Indicative of Insulin Resistance and Prediabetes in Overweight and Obese Subjects
Profil Institut für Stoffwechselforschung GmbH1 site in 1 country106 target enrollmentSeptember 25, 2013
ConditionsPrediabetes
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prediabetes
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Enrollment
- 106
- Locations
- 1
- Primary Endpoint
- anthropometric measures and metabolic biomarkers indicative of prediabetes
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The rationale for this trial is to apply a simple and minimally strenuous pre-screening approach prior to performing more extensive trial-specific screening and baseline-characterization activities in the resulting pre-selected population of subjects.
Detailed Description
The pre-screening assessments are designed to characterize the metabolic risk profile / prediabetic status in an unselected population of overweight and obese volunteers, aiming to pre-select high risk and prediabetic subjects as a target population who may specifically profit from primary diabetes intervention (prevention) strategies.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Obese and overweight subjects
- •Considered generally healthy
Exclusion Criteria
- •Clinically significant acute illness within 2 weeks before study procedures
Outcomes
Primary Outcomes
anthropometric measures and metabolic biomarkers indicative of prediabetes
Time Frame: Day one
One blood sample taken on day 1 of the study
Secondary Outcomes
- intra-subject and inter-subject variability of analyzed biomarkers(within one month)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancerJPRN-UMIN000010429EPS Corporation100
Completed
Not Applicable
The exploratory study to evaluate biomarkers in prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer (J-TAIL-2)on-small cell lung cancer or extensive disease small cell lung cancerJPRN-UMIN000043663CHUGAI PHARMACEUTICAL CO., LTD.450
Completed
Not Applicable
Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial MyopathiesMitochondrial MyopathiesHealthy ControlsNCT03513835Rigshospitalet, Denmark50
Not yet recruiting
Not Applicable
Exploratory research of biomarkers for investigational drugs using tear fluid samplesJPRN-UMIN000049186Santen Pharmaceutical Co. Ltd.29
Completed
Not Applicable
Asthma Biomarker StudyAsthmaNCT02392481Boehringer Ingelheim69